Virtual Library

Start Your Search

N. Abdel-Rahman

Author of

  • +

    Poster Display Session (ID 63)

    • Event: ELCC 2017
    • Type: Poster Display Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 5/07/2017, 12:30 - 13:00, Hall 1
    • +

      68P - Circulating tumor cells spillage after lung nodule biopsy (ID 497)

      12:30 - 13:00  |  Author(s): N. Abdel-Rahman

      • Abstract

      Lung cancer has high recurrence rate even when diagnosed at an early stage. Biopsy is currently the procedure of choice for the investigation of pulmonary lesions, yet it is unclear whether the biopsy itself releases tumor cells into the circulation and attributes to the late distal recurrence. Studies of various malignancies show the ability to identify circulating tumor cells (CTC) even in early stage cancer. The number of CTC correlates with disease outcome. The aim of this study was to quantify the spillage of tumor cells after nodule biopsy in early lung cancer.

      Patients with pulmonary nodules undergoing computed tomography biopsy enrolled into this study. CellCollector[TM] (GILUPI, Germany) was used for CTC detection before and after the procedure. This filtration device isolates CTC in-vivo through a standard cannula inserted to the cubbital vein for thirty minutes via epithelial cell adhesion molecule antibodies. Patients served as their own controls. Trans thoracic biopsy was done by a 19G needle with a standard procedure of one pass. The study was approved by the institutions' ethics committee.

      13 patients were enrolled to between 02/2016 and 08/2016. Five patients were excluded due to partial procedure. Eight patients were eligible for analysis. Three had benign diseases (Granuloma, Interstitial pneumonitis. and five had lung cancer (Adenocarcinoma -4; Squamous-1); 3 had an elevation of the CTC count (0->2, 0->3, 2->8) and 2 had a depletion (8->2, 5->2). All 5 patients were male, with a median age of 65 years (range 54-72), four of them were past smokers and one never smoker. No adverse events were reported.

      With the limitation of low number of participants, this preliminary data shows that trans thoracic biopsy may increase CTC in some patients with lung cancer. The study is ongoing and the enlarged cohort will be presented.

      Clinical trial identification:

      Legal entity responsible for the study:
      Rabin Medical Center Ethics Comittee


      J. Pfannkuche: Managing director at GILUPI, which provided the kits for this study. C. Chudak: Marketing & Sales Manager at GILUPI, which provided the kits for this study. All other authors have declared no conflicts of interest.